Lamivudine-based two-drug regimens with dolutegravir or protease inhibitor: Virological suppression in spite of previous therapy failure or renal dysfunction
CONCLUSIONS: The 2DR is feasible, with robust suppression rates, even when 3TC resistance or renal dysfunction is present, and close monitoring of these cases may guarantee long-term suppression.PMID:36809850 | DOI:10.1016/j.bjid.2023.102757 (Source: Braz J Infect Dis)
Source: Braz J Infect Dis - February 22, 2023 Category: Infectious Diseases Authors: Elaine Monteiro Matsuda Ivana Barros Campos Isabela Penteriche de Oliveira Daniela Rodrigues Colpas Giselle Ibete Silva L ópez-Lopes Victor Oliveira Chiavegato Lu ís Fernando de Macedo Brígido Source Type: research
Lamivudine-based two-drug regimens with dolutegravir or protease inhibitor: Virological suppression in spite of previous therapy failure or renal dysfunction
CONCLUSIONS: The 2DR is feasible, with robust suppression rates, even when 3TC resistance or renal dysfunction is present, and close monitoring of these cases may guarantee long-term suppression.PMID:36809850 | DOI:10.1016/j.bjid.2023.102757 (Source: Braz J Infect Dis)
Source: Braz J Infect Dis - February 22, 2023 Category: Infectious Diseases Authors: Elaine Monteiro Matsuda Ivana Barros Campos Isabela Penteriche de Oliveira Daniela Rodrigues Colpas Giselle Ibete Silva L ópez-Lopes Victor Oliveira Chiavegato Lu ís Fernando de Macedo Brígido Source Type: research
Lamivudine-based two-drug regimens with dolutegravir or protease inhibitor: Virological suppression in spite of previous therapy failure or renal dysfunction
CONCLUSIONS: The 2DR is feasible, with robust suppression rates, even when 3TC resistance or renal dysfunction is present, and close monitoring of these cases may guarantee long-term suppression.PMID:36809850 | DOI:10.1016/j.bjid.2023.102757 (Source: Braz J Infect Dis)
Source: Braz J Infect Dis - February 22, 2023 Category: Infectious Diseases Authors: Elaine Monteiro Matsuda Ivana Barros Campos Isabela Penteriche de Oliveira Daniela Rodrigues Colpas Giselle Ibete Silva L ópez-Lopes Victor Oliveira Chiavegato Lu ís Fernando de Macedo Brígido Source Type: research
Lamivudine-based two-drug regimens with dolutegravir or protease inhibitor: Virological suppression in spite of previous therapy failure or renal dysfunction
CONCLUSIONS: The 2DR is feasible, with robust suppression rates, even when 3TC resistance or renal dysfunction is present, and close monitoring of these cases may guarantee long-term suppression.PMID:36809850 | DOI:10.1016/j.bjid.2023.102757 (Source: Braz J Infect Dis)
Source: Braz J Infect Dis - February 22, 2023 Category: Infectious Diseases Authors: Elaine Monteiro Matsuda Ivana Barros Campos Isabela Penteriche de Oliveira Daniela Rodrigues Colpas Giselle Ibete Silva L ópez-Lopes Victor Oliveira Chiavegato Lu ís Fernando de Macedo Brígido Source Type: research
Lamivudine-based two-drug regimens with dolutegravir or protease inhibitor: Virological suppression in spite of previous therapy failure or renal dysfunction
CONCLUSIONS: The 2DR is feasible, with robust suppression rates, even when 3TC resistance or renal dysfunction is present, and close monitoring of these cases may guarantee long-term suppression.PMID:36809850 | DOI:10.1016/j.bjid.2023.102757 (Source: Braz J Infect Dis)
Source: Braz J Infect Dis - February 22, 2023 Category: Infectious Diseases Authors: Elaine Monteiro Matsuda Ivana Barros Campos Isabela Penteriche de Oliveira Daniela Rodrigues Colpas Giselle Ibete Silva L ópez-Lopes Victor Oliveira Chiavegato Lu ís Fernando de Macedo Brígido Source Type: research
Lamivudine-based two-drug regimens with dolutegravir or protease inhibitor: Virological suppression in spite of previous therapy failure or renal dysfunction
CONCLUSIONS: The 2DR is feasible, with robust suppression rates, even when 3TC resistance or renal dysfunction is present, and close monitoring of these cases may guarantee long-term suppression.PMID:36809850 | DOI:10.1016/j.bjid.2023.102757 (Source: Braz J Infect Dis)
Source: Braz J Infect Dis - February 22, 2023 Category: Infectious Diseases Authors: Elaine Monteiro Matsuda Ivana Barros Campos Isabela Penteriche de Oliveira Daniela Rodrigues Colpas Giselle Ibete Silva L ópez-Lopes Victor Oliveira Chiavegato Lu ís Fernando de Macedo Brígido Source Type: research
Lamivudine-based two-drug regimens with dolutegravir or protease inhibitor: Virological suppression in spite of previous therapy failure or renal dysfunction
CONCLUSIONS: The 2DR is feasible, with robust suppression rates, even when 3TC resistance or renal dysfunction is present, and close monitoring of these cases may guarantee long-term suppression.PMID:36809850 | DOI:10.1016/j.bjid.2023.102757 (Source: Braz J Infect Dis)
Source: Braz J Infect Dis - February 22, 2023 Category: Infectious Diseases Authors: Elaine Monteiro Matsuda Ivana Barros Campos Isabela Penteriche de Oliveira Daniela Rodrigues Colpas Giselle Ibete Silva L ópez-Lopes Victor Oliveira Chiavegato Lu ís Fernando de Macedo Brígido Source Type: research
Lamivudine-based two-drug regimens with dolutegravir or protease inhibitor: Virological suppression in spite of previous therapy failure or renal dysfunction
CONCLUSIONS: The 2DR is feasible, with robust suppression rates, even when 3TC resistance or renal dysfunction is present, and close monitoring of these cases may guarantee long-term suppression.PMID:36809850 | DOI:10.1016/j.bjid.2023.102757 (Source: Braz J Infect Dis)
Source: Braz J Infect Dis - February 22, 2023 Category: Infectious Diseases Authors: Elaine Monteiro Matsuda Ivana Barros Campos Isabela Penteriche de Oliveira Daniela Rodrigues Colpas Giselle Ibete Silva L ópez-Lopes Victor Oliveira Chiavegato Lu ís Fernando de Macedo Brígido Source Type: research
Lamivudine-based two-drug regimens with dolutegravir or protease inhibitor: Virological suppression in spite of previous therapy failure or renal dysfunction
CONCLUSIONS: The 2DR is feasible, with robust suppression rates, even when 3TC resistance or renal dysfunction is present, and close monitoring of these cases may guarantee long-term suppression.PMID:36809850 | DOI:10.1016/j.bjid.2023.102757 (Source: Braz J Infect Dis)
Source: Braz J Infect Dis - February 22, 2023 Category: Infectious Diseases Authors: Elaine Monteiro Matsuda Ivana Barros Campos Isabela Penteriche de Oliveira Daniela Rodrigues Colpas Giselle Ibete Silva L ópez-Lopes Victor Oliveira Chiavegato Lu ís Fernando de Macedo Brígido Source Type: research
Lamivudine-based two-drug regimens with dolutegravir or protease inhibitor: Virological suppression in spite of previous therapy failure or renal dysfunction
CONCLUSIONS: The 2DR is feasible, with robust suppression rates, even when 3TC resistance or renal dysfunction is present, and close monitoring of these cases may guarantee long-term suppression.PMID:36809850 | DOI:10.1016/j.bjid.2023.102757 (Source: Braz J Infect Dis)
Source: Braz J Infect Dis - February 22, 2023 Category: Infectious Diseases Authors: Elaine Monteiro Matsuda Ivana Barros Campos Isabela Penteriche de Oliveira Daniela Rodrigues Colpas Giselle Ibete Silva L ópez-Lopes Victor Oliveira Chiavegato Lu ís Fernando de Macedo Brígido Source Type: research
Lamivudine-based two-drug regimens with dolutegravir or protease inhibitor: Virological suppression in spite of previous therapy failure or renal dysfunction
CONCLUSIONS: The 2DR is feasible, with robust suppression rates, even when 3TC resistance or renal dysfunction is present, and close monitoring of these cases may guarantee long-term suppression.PMID:36809850 | DOI:10.1016/j.bjid.2023.102757 (Source: Braz J Infect Dis)
Source: Braz J Infect Dis - February 22, 2023 Category: Infectious Diseases Authors: Elaine Monteiro Matsuda Ivana Barros Campos Isabela Penteriche de Oliveira Daniela Rodrigues Colpas Giselle Ibete Silva L ópez-Lopes Victor Oliveira Chiavegato Lu ís Fernando de Macedo Brígido Source Type: research
Lamivudine-based two-drug regimens with dolutegravir or protease inhibitor: Virological suppression in spite of previous therapy failure or renal dysfunction
CONCLUSIONS: The 2DR is feasible, with robust suppression rates, even when 3TC resistance or renal dysfunction is present, and close monitoring of these cases may guarantee long-term suppression.PMID:36809850 | DOI:10.1016/j.bjid.2023.102757 (Source: Braz J Infect Dis)
Source: Braz J Infect Dis - February 22, 2023 Category: Infectious Diseases Authors: Elaine Monteiro Matsuda Ivana Barros Campos Isabela Penteriche de Oliveira Daniela Rodrigues Colpas Giselle Ibete Silva L ópez-Lopes Victor Oliveira Chiavegato Lu ís Fernando de Macedo Brígido Source Type: research
Lamivudine-based two-drug regimens with dolutegravir or protease inhibitor: Virological suppression in spite of previous therapy failure or renal dysfunction
CONCLUSIONS: The 2DR is feasible, with robust suppression rates, even when 3TC resistance or renal dysfunction is present, and close monitoring of these cases may guarantee long-term suppression.PMID:36809850 | DOI:10.1016/j.bjid.2023.102757 (Source: Braz J Infect Dis)
Source: Braz J Infect Dis - February 22, 2023 Category: Infectious Diseases Authors: Elaine Monteiro Matsuda Ivana Barros Campos Isabela Penteriche de Oliveira Daniela Rodrigues Colpas Giselle Ibete Silva L ópez-Lopes Victor Oliveira Chiavegato Lu ís Fernando de Macedo Brígido Source Type: research
Lamivudine-based two-drug regimens with dolutegravir or protease inhibitor: Virological suppression in spite of previous therapy failure or renal dysfunction
CONCLUSIONS: The 2DR is feasible, with robust suppression rates, even when 3TC resistance or renal dysfunction is present, and close monitoring of these cases may guarantee long-term suppression.PMID:36809850 | DOI:10.1016/j.bjid.2023.102757 (Source: Braz J Infect Dis)
Source: Braz J Infect Dis - February 22, 2023 Category: Infectious Diseases Authors: Elaine Monteiro Matsuda Ivana Barros Campos Isabela Penteriche de Oliveira Daniela Rodrigues Colpas Giselle Ibete Silva L ópez-Lopes Victor Oliveira Chiavegato Lu ís Fernando de Macedo Brígido Source Type: research
Mechanistic in vitro studies indicate that the clinical drug –drug interactions between protease inhibitors and rosuvastatin are driven by inhibition of intestinal BCRP and hepatic OATP1B1 with minimal contribution from OATP1B3, NTCP and OAT3
This work sought to clarify the mechanisms underlying clinical DDIs between rosuvastatin and protease inhibitors. Investigating in vitro inhibition of the critical transporter disposition pathways of rosuvastatin, and subsequent incorporation of cell test system derived determined Ki values into mechanistic static equations, enabled successful quantitative prediction of clinical AUCRs. Predictions suggest the mechanisms driving DDI are principally inhibition of intestinal BCRP and hepatic OATP1B1, with minimal contribution from OATP1B3, NTCP or OAT3. AbstractPrevious use of a mechanistic static model to accurately quantify...
Source: Pharmacology Research and Perspectives - February 22, 2023 Category: Drugs & Pharmacology Authors: Robert Elsby,
Hannah Coghlan,
Jacob Edgerton,
David Hodgson,
Samuel Outteridge,
Hayley Atkinson Tags: ORIGINAL ARTICLE Source Type: research
